Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

M G Bousser, M Amarenco, A Chamorro, M Fisher, I Ford, K Fox, Michael Hennerici, H P Mattle, Peter Malcolm W Rothwell, Christopher Bladin

Research output: Contribution to journalArticleResearchpeer-review

66 Citations (Scopus)
Original languageEnglish
Pages (from-to)509 - 518
Number of pages10
JournalCerebrovascular Diseases
Issue number5
Publication statusPublished - 2009

Cite this